News

On January 13th, the signing ceremony for the strategic cooperation between Autobio and Boditech Med Inc (hereinafter referred to as Boditech) was held at Boditech's campus in Chuncheon City, South Korea, in the presence of Mr. Fu Guangyu, Executive Vice President of Autobio, and Mr. Eui Yul Choi, Chief Executive Officer (CEO) of Boditech. Mr. Eui Yul Choi, CEO of Boditech, participated in the signing ceremony. Both parties will fully utilize their respective advantages in the field of in vitro diagnostics to carry out in-depth cooperation in the field of immunoassay.

During this period, the two sides had in-depth exchanges and discussions on strategic cooperation. Mr. Fu Guangyu, Executive Vice President, introduced the innovative development of Autobio. He said that the strategic cooperation between Autobio and Boditech reflects the complementary advantages and synergistic innovation of the two sides. We believe that this cooperation will bring new opportunities and wider development space for both sides, and we look forward to working hand in hand with Boditech for joint development and mutual benefit and win-win situation.

Mr. Eui Yul Choi said in his speech that Boditech attaches great importance to this cooperation, which will be conducive to promoting the joint development of the market and enhancing each other's innovation and competitiveness, and he looks forward to deepening the strategic partnership with Autobio and realizing more extensive cooperation in the field of immunoassay.

As a world-renowned IVD company, Boditech has been deeply involved in point-of-care testing (POCT) since its establishment in 1998, demonstrating outstanding professional strength and technological innovation. With its profound accumulation and continuous exploration in the POCT field, Boditech was successfully listed in Korea in 2015, and its globalization strategy has achieved remarkable success. Boditech's products have been certified by FDA, CE, CFDA, KFDA, JPAL, etc., and have been sold to more than 140 countries worldwide, with about 140,000 fluorescence immunoassay analyzers installed worldwide, and its CRP (C-Reactive Protein) products have high competitiveness in the market. Boditech is committed to the research and development of in vitro diagnostic equipment and reagents based on the concept of "respecting the value of life". Boditech currently has a number of technology platforms such as immunofluorescence, chemiluminescence and colloidal gold, and its products cover a wide range of clinical areas such as cardiovascular diseases, infections, endocrine and digestive systems, etc. Boditech has obtained nearly one hundred medical device registration certificates and has led the development of the in vitro diagnostic industry with its innovative rapid diagnostic technology for whole blood.

The strategic agreement marks a new stage in the cooperation between Autobio and Boditech in the field of in vitro diagnostics. The two companies will jointly explore the Korean market, promote the innovative development of immunoassay technology, and provide more accurate and efficient products and services to patients worldwide.